Phase 2 study of <scp>RO</scp>4929097, a gamma‐secretase inhibitor, in metastatic melanoma: <scp>SWOG</scp> 0933

RO4929097 showed minimal clinical activity against metastatic melanoma in this phase 2 trial, possibly because of inadequate exposure to therapeutic drug levels. Although Notch inhibition remains a compelling target in melanoma, the results do not support further investigation of RO4929097 with this dose and schedule.